In short
Clinical trials of TRIACYLGLYCEROL LIPASE are studying a new lipase treatment in adults with exocrine pancreatic insufficiency. These trials mainly look at safety and early signs of benefit compared with pancrelipase. The goal is to see how well it works in people who need help digesting food.
Key points
- Clinical trials of TRIACYLGLYCEROL LIPASE are focused on adults with exocrine pancreatic insufficiency. The listed study is a Phase 2 interventional trial with 44 participants. It compares a new lipase treatment, NHS7108, with pancrelipase. The main goals are to check safety and look for early signs that the treatment may help. Researchers are measuring adverse events, lab tests, vital signs, ECG results, physical exam findings, and coefficient of nitrogen absorption.
Trial overview
The available trial for TRIACYLGLYCEROL LIPASE is a Phase 2 interventional study in adults with exocrine pancreatic insufficiency (EPI).1 It is authorised and plans to enroll 44 participants.1
The study title says it will evaluate safety and explore efficacy of a new lipase called NHS7108 compared with pancrelipase.1 “Efficacy” means how well a treatment works.1
Who is being studied
This trial is for adult participants with exocrine pancreatic insufficiency.1 EPI is the condition being studied, and the trial data do not give more detailed eligibility rules.1
People in this study are being followed because they need support with digestion and nutrient absorption.1 The study is not described as a pediatric trial, so the listed population is adults only.1
What is being tested
The study compares NHS7108 capsules with Zenpep delayed-release capsules, which are listed as pancrelipase in the trial record.1 Both are given by mouth.1
The brief summary says different doses of NHS7108 are given daily for 14 days in participants with EPI.1 This means the researchers are looking at short-term treatment effects over two weeks.1
Study phase and design
This is an interventional trial, which means participants receive a study treatment and researchers observe the effects.1 It is a Phase 2 study, so the main focus is safety with early signs of benefit.1
Phase 2 studies often help researchers decide whether a treatment should be studied further in larger groups.1 In this trial, the study is also meant to compare the new treatment with an existing one used for the same condition.1
What outcomes are measured
The main safety outcome is the number of participants who report one or more adverse events.1 An adverse event is any unwanted health problem that happens during the study.1
Researchers also track changes from baseline in safety parameters after 14 days of NHS7108 treatment.1 These safety checks include clinical laboratory tests, vital signs, 12-lead electrocardiogram (ECG), and physical examination.1
Another key measure is the change from baseline in coefficient of nitrogen absorption (CNA) after 14 days.1 CNA is used here as a way to assess how well the body absorbs nitrogen, which helps show protein absorption.1
How to read the study results
Because this is a small Phase 2 study, the results will mainly help show whether the treatment is safe enough and whether it may be worth studying more.1 The study does not yet provide final proof that the treatment works better than the comparison treatment.1
For patients, the most important points are the condition studied, the adult population, the short 14-day treatment period, and the safety-focused outcomes.1 These details show that the trial is an early step in learning more about TRIACYLGLYCEROL LIPASE-related treatment research.1